Novartis delivers strong new product momentum and operational performance
- Details
- Category: Novartis
Novartis maintained the strong underlying momentum of 2009 as third-quarter net sales grew 7% in local currencies, while reported net sales rose 3% to USD 11.1 billion as four percentage points of growth were lost to adverse currency movements.
Merck Revenues Increase by 2.7% to € 1.9 Billion
- Details
- Category: Merck Group
Merck KGaA announced that Group total revenues rose 2.7% in the third quarter to € 1,944 million from € 1,893 million in the year-ago quarter as the Pharmaceuticals divisions continued to grow and the Chemicals divisions continued to recover from the economic crisis. Royalty income declined 9.7% to € 82 million.
FDA Determines VYVANSE® was Properly Granted Five-Year Market Exclusivity
- Details
- Category: Shire
Shire plc (LSE: SHP, NASDAQ: SHPGY), the global specialty biopharmaceutical company, announces that the Food and Drug Administration (FDA), following a thorough administrative review of governing statutory and regulatory standards and public comments, has affirmed its prior decision to grant five-year New Chemical Entity (NCE) exclusivity to lisdexamfetamine dimesylate
Sanofi-aventis and Wellstat Therapeutics enter into an Exclusive Worldwide Licensing Agreement
- Details
- Category: Sanofi
Sanofi-aventis (EURONEXT: SAN and NYSE: SNY) and Wellstat Therapeutics Corporation announced a global licensing agreement on PN2034, a novel oral first-in-class, insulin sensitizer, for the treatment of Type II Diabetes. As a sensitizer, PN2034 is expected to normalize and therefore enhance insulin action in the liver of diabetic patients. The compound is currently in Phase II clinical testing.
Bayer and Onyx Initiate Phase III Trial of Nexavar® in Patients with Non-Responsive Thyroid Cancer
- Details
- Category: Bayer
Bayer HealthCare AG and Onyx Pharmaceuticals, Inc. today announced that the companies have begun enrolling patients in an international Phase III trial to evaluate Nexavar® (sorafenib) tablets for the treatment of patients with radioactive iodine-refractory, locally advanced or metastatic differentiated thyroid cancer.
Bayer and Onyx Initiate Phase III Trial of Nexavar in Patients with Non-Responsive Thyroid Cancer
- Details
- Category: Bayer
Bayer HealthCare AG and Onyx Pharmaceuticals, Inc. today announced that the companies have begun enrolling patients in an international Phase III trial to evaluate Nexavar® (sorafenib) tablets for the treatment of patients with radioactive iodine-refractory, locally advanced or metastatic differentiated thyroid cancer.
Bristol-Myers Squibb Achieves Strong Sales
- Details
- Category: Bristol-Myers Squibb
Bristol-Myers Squibb posted third quarter 2009 net sales from continuing operations of $5.5 billion, an increase of 4%, or 7% excluding foreign exchange impact, compared to the same period in 2008.
More Pharma News ...
- The 4-T study of intensified insulin regimens shows excellent three-year glucose control
- Amgen's Third Quarter 2009 Adjusted Earnings Per Share Increased 21 Percent
- Pfizer Reports Third-Quarter 2009 Results
- Novartis drug Tasigna® meets primary endpoint in pivotal trial against Glivec®
- Abbott Completes Visiogen Acquisition
- FDA approves Cervarix, GlaxoSmithKline's cervical cancer vaccine
- FDA approves Micardis® (telmisartan) as the first treatment in its class